About Lentigen
Lentigen is a Healthcare company based in Gaithersburg (United States) founded in 2004, and was acquired by Miltenyi Biotec in August 2014. Lentiviral vectors are developed for pre-clinical and clinical applications. Lentigen has completed 1 acquisition, including Living Pharma. The company was acqui-hired. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include StrideBio, LogicBio and Phase Genomics; 3 of its 3 listed competitors have raised funding.
Company details
Lentigen was founded in 2004 in Gaithersburg, United States, focusing on the biotechnology sector. Lentiviral vectors are manufactured for translational research, including multi-lentiviral vector evaluation for construct assessment, custom concentrated vectors for feasibility studies, and chromatography-purified vectors for process evaluation. Operations support pre-clinical and clinical applications in gene therapy and related fields.
- Headquarters Gaithersburg, United States
- Stage Acquired
- SectorsHealthcare
- Website lentigen.com/home
- Social LinkedIn X
- Acquired by Miltenyi Biotec (Aug 2014)
- Latest Funding Round$1.2M (USD), Grant
Nov 2010
- InvestorsMiltenyi Biotec
& 1 more
- Investments & Acquisitions
- Acquired byMiltenyi Biotec
(Aug 2014)
Funding Insights of Lentigen
- Total Rounds 12
- Last Round Grant — $1.2M
- Investors Count 1
Latest 10 of 12 funding rounds of Lentigen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2010 | $1.2M | Grant | – | – | – |
| Sep 2010 | $2.65M | Grant | – | – | |
| Jun 2010 | $4.78M | Grant | – | – | |
| Apr 2010 | $364,844 | Grant | – | – | |
| Mar 2010 | $364,844 | Grant | – | – | |
| Sep 2009 | $423,638 | Grant | – | – | |
| Aug 2009 | $140,720 | Grant | – | – | |
| Aug 2009 | $282,918 | Grant | – | – | |
| Sep 2008 | $119,144 | Grant | – | – | |
| Sep 2008 | $119,144 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Lentigen
Lentigen has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Miltenyi Biotec and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Develops tools and products for research and clinical application | 1989 | miltenyibiotec.com | Bergisch Gladbach, Germany |
Investor details for Lentigen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lentigen
Lentigen has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Living Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Personalized anti-tag CAR T cell therapies for cancer are developed. | livingpharma.com | Baltimore, United States | 2015 | Jul 2017 | •••• |
Complete acquisition details for Lentigen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lentigen
5 dated milestones of Lentigen across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Lentigen is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $1.2M.
- Exit Acquired by Miltenyi Biotec.
- Acquisition Acquires Living Pharma.
Competitors of Lentigen
Lentigen has 3 listed competitors in our database, 3 of them funded. They include StrideBio, LogicBio and Phase Genomics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. |
Detailed competitors of Lentigen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Lentigen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lentigen
Complete news archive for Lentigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lentigen
Lentigen was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Lentigen is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Lentigen was founded in 2004 in Gaithersburg, United States, focusing on the biotechnology sector. Lentiviral vectors are manufactured for translational research, including multi-lentiviral vector evaluation for construct assessment, custom concentrated vectors for feasibility studies, and chromatography-purified vectors for process evaluation. Operations support pre-clinical and clinical applications in gene therapy and related fields.
Lentigen's top competitors include Phase Genomics, LogicBio and StrideBio.
Lentigen has made 1 acquisition, including Living Pharma.
Lentigen has 2 investors. Key investors include Miltenyi Biotec, and HHS.
Yes. Lentigen was acquired by Miltenyi Biotec in August 2014.